News
Throwing oil into the flames
Obesity has become one of the leading preventable causes of cancer. Yet, the mechanisms of how obesity and associated systemic inflammation can promote cancer progression remain poorly understood. In a new study, researchers found that the cytokines interleukin 5 (IL-5) and granulocyte macrophage colony-stimulating factor (GM-CSF) are induced in obesity and, in obese mice, this leads to lung neutrophilia and supports breast cancer metastasis to the lung. Quail, Olson et al. used mouse models of obesity, induced by a high-fat diet (diet-induced obesity, DIO mice) or leptin deficiency (ob/ ob mice), to study how inflammation in obesity is linked to breast cancer metastasis.
Tackling the Obesity and Cancer Epidemic (ASCO May 25, 2017)
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining the preventive effects of weight control on cancer risk […]
SynDevRx will be attending ASCO (Chicago) June 3–7
The ASCO Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Epidemiologic data suggest that T2DM is associated with an increased incidence and mortality from many cancers. The purpose of this review is to discuss the links between diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortality, and the effects of anticancer therapies on diabetes.
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation
There is growing evidence that inflammation is a central and reversible mechanism through which obesity promotes cancer risk and progression.
Obesity and Cancer: Insights for Clinicians
The association of obesity with cancer, increasingly recognized in both lay and medical communities and underscored by the ongoing obesity epidemic, has stimulated a large body of research and led to calls for programs to minimize any potential impact of obesity on cancer
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
We reviewed the literature regarding overweight and obesity and breast cancer survival outcomes, overall and with regard to breast cancer subtypes, breast cancer therapies, biologic mechanisms, and possible interventions.
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Observational studies have reported a modest association between obesity and risk of ovarian cancer; however, whether it is also associated with survival and whether this association varies for the different histologic subtypes are not clear. We undertook an international collaborative analysis to assess the association between body mass index (BMI), assessed shortly before diagnosis, progression-free survival (PFS), ovarian cancer-specific survival and overall survival (OS) among women with invasive ovarian cancer.
Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer
Although several studies have established a link between obesity and colon cancer risk, little is known about the effect of obesity on outcomes after diagnosis. We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials.
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
Body-mass index (the weight in kilograms divided by the square of the height in meters) is known to be associated with overall mortality. We investigated the effects of age, race, sex, smoking status, and history of disease on the relation between body-mass index and mortality.